Zyrtec Ads Not “On The Ball,” Make Misleading Claims – FDA Warning Letter
This article was originally published in The Tan Sheet
Executive Summary
Ads for Pfizer's Zyrtec (cetirizine) make unsubstantiated superiority claims to other allergy medicines, FDA's Division of Drug Marketing, Advertising & Communications says in an April 13 warning letter
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning